Transduction Buffer for Protein Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for introducing proteins and other macromolecules into cells, particularly primary cells, are inefficient, non-specific, and often toxic, limiting their therapeutic and scientific applications.
Innovation Solution
A transduction buffer comprising a combination of a transduction compound, a sodium-related salt, a further osmolality-inducing component, and an osmoprotectant, which increases the osmolality of the buffer to enhance the efficiency and speed of protein transduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If TAT-peptide mediated protein transduction is used, then transduction works with all cell types including primary cells, but the strong positive charge of the TAT peptide severely hampers production of native recombinant TAT-fusion proteins in E. coli with much of the recombinant protein ending up in inclusion bodies
Solution Approach 1:
The patent extracts the transduction function from the TAT peptide by using a transduction buffer that mediates protein entry without requiring fusion to charged peptides. This separates the transduction capability from the cargo protein, allowing native recombinant proteins to be produced in E. coli without the manufacturing problems associated with TAT-fusion proteins.
Solution Approach 2:
The transduction buffer acts as an intermediary that facilitates protein transduction into cells without requiring the protein to be fused to a charged peptide. The buffer components (hypertonic solution, detergents, protease inhibitors) mediate the entry process, eliminating the need for TAT peptide fusion and its associated production challenges.
2Adaptability or versatility
If TAT peptide is fused to the cargo protein to enable transduction, then cell transduction is achieved, but the TAT peptide itself can disrupt the function or localization of the recombinant protein leading to unexpected or unwanted results
Solution Approach 1:
The patent removes the TAT peptide from the transduction process by using a transduction buffer instead. This extraction eliminates the risk of the TAT peptide disrupting protein function or localization, as the buffer mediates entry without requiring peptide-protein fusion that could interfere with the cargo's native properties.
Solution Approach 2:
The transduction buffer serves as an intermediary that enables protein entry into cells without the cargo protein being fused to TAT peptide. This intermediary approach preserves the native structure, function, and localization of the recombinant protein while still achieving transduction.
3Productivity
If traditional transfection methods using cationic lipids or viral vectors are used, then nucleotides and therapeutic molecules can be introduced into cells, but these methods result in significant risk of adverse reactions including acute immune rejection and tumor formation
Solution Approach 1:
The patent uses a disposable transduction buffer system that performs transduction in a single step without requiring viral vectors or complex transfection reagents. This eliminates the long-term risks associated with viral integration and immune rejection, as the buffer completes its function and is removed, leaving no persistent harmful elements in the cell.
Solution Approach 2:
The transduction buffer acts as a temporary intermediary that facilitates molecule introduction into cells without the use of viral vectors or cationic lipids that cause immune reactions. The buffer mediates the transduction process and is then removed, eliminating the source of adverse reactions while maintaining transduction efficiency.
4Productivity
If hypertonic treatment followed by brief hypotonic treatment is used to induce intracellular uptake of macromolecules, then protein transduction is achieved in immortalized cell lines, but this technique proves limited to immortalized cell lines and yields poor protein transduction efficiencies in primary cells
Solution Approach 1:
The transduction buffer is designed to work universally across different cell types including primary cells, immortalized cell lines, and stem cells. The combination of hypertonic solution, non-ionic detergents, and protease inhibitors creates a multi-functional system that adapts to different cell types without requiring optimization for each specific line, achieving both high efficiency and broad applicability.
Solution Approach 2:
The patent optimizes specific parameters of the transduction buffer including osmolality (hypertonic conditions), detergent concentration (0.01-1% non-ionic detergent), and protease inhibitor presence to achieve high transduction efficiency across diverse cell types. These parameter adjustments enable the buffer to work effectively with primary cells that have different membrane properties compared to immortalized lines.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly shortens the time required for protein transduction, allowing for the efficient introduction of large proteins and gene editing tools into cells both in vitro and in vivo, while maintaining cell viability.
Implementation Method 1
A transduction buffer comprising a combination of a transduction compound, a sodium-related salt, a further osmolality-inducing component, and an osmoprotectant, which increases the osmolality of the buffer to enhance the efficiency and speed of protein transduction
Data Source
AI summary
The invention relates to transduction compounds, buffers and methods for introducing molecules into cells. The invention also relates to methods of treatment, pharmaceutical compositions and other uses of the transduction compounds and buffers. The invention also relates to modified cells obtainable by the transduction compounds, buffers and methods of the invention.